Stay updated on Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.

Latest updates to the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page
- Check7 days agoChange DetectedCore trial information appears unchanged; only minor visual or formatting differences are present in the page layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check14 days agoChange DetectedRevision: v3.4.2 was added; the lapse-in-government-funding notice and related operating-status updates were removed.SummaryDifference0.2%

- Check21 days agoChange DetectedA government funding notice was added and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check28 days agoChange DetectedThe page now shows a glossary and new metadata fields (Last Update Submitted that Met QC Criteria, Revision: v3.4.0) and removes older metadata (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These changes are UI and metadata tweaks and do not alter core study content or patient-facing information.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. This metadata update does not affect study content or outcomes.SummaryDifference0.0%

- Check63 days agoChange DetectedLocations section expanded to include US states and Canadian provinces, listing numerous sites; page revision updated to v3.3.3.SummaryDifference1%

Stay in the know with updates to Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib+Pembrolizumab in Metastatic Gastroesophageal Cancer Clinical Trial page.